

Case Report

Open Access



Biallelic cubilin pathogenic variants as a cause of « benign » proteinuria: implications for clinical management

Valentine Gillion^{1,2}, Karin Dahan^{1,3}, Nathalie Godefroid^{2,4}

¹Division of Nephrology, Cliniques universitaires Saint-Luc, Brussels B-1200, Belgium.

²Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels B-1200, Belgium.

³Centre de Génétique Humaine, Institut de Pathologie et de Génétique, Gosselies 6041, Belgium.

⁴Division of Pediatric Nephrology, Cliniques universitaires Saint-Luc, Brussels B-1200, Belgium.

Correspondence to: Dr. Valentine Gillion, Division of Nephrology, Cliniques universitaires Saint-Luc, Avenue Hippocrate 10, Brussels B-1200, Belgium. E-mail: valentine.gillion@uclouvain.be

How to cite this article: Gillion V., Dahan K., Godefroid N.. Biallelic cubilin pathogenic variants as a cause of « benign » proteinuria: implications for clinical management. *Rare Dis Orphan Drugs J.* 2023;2:11. <https://dx.doi.org/10.20517/rdodj.2022.23>

Received: 15 Nov 2022 **First Decision:** 23 Feb 2023 **Revised:** 24 Apr 2023 **Accepted:** 8 May 2023 **Published:** 15 May 2023

Academic Editors: Daniel Scherman, Jacques S Beckmann **Copy Editor:** Yanbing Bai **Production Editor:** Yanbing Bai

Abstract

The recent description of a cohort with both adults and children harboring biallelic pathogenic variants of cubilin (*CUBN*) changed the paradigm for the management of isolated proteinuria. Indeed, the detection of proteinuria in a patient, regardless of age, often leads to an exhaustive check-up, including a kidney biopsy, but also to the prescription of renin-angiotensin system (RAS) blockers to slow the progression of kidney disease. Patients with *CUBN* variants have nondetrimental proteinuria and are non-responsive to RAS blockers. We herein describe two siblings treated for isolated proteinuria for several years, who were eventually diagnosed with *CUBN* biallelic pathogenic variants (c.703 C > T and c.10363-3A > G). We review the pathophysiological mechanisms of this newly discovered disease and discuss its implications for clinical management.

Keywords: Proteinuria, genetic kidney disease, cubilin, isolated albuminuria

INTRODUCTION

Discovering isolated proteinuria in a patient should lead to an appropriate work-up, including biological



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.



analysis, kidney ultrasound, and, in some cases, kidney biopsy. Proteinuria may be glomerular (mainly albuminuria with or without microscopic hematuria), tubular (low molecular weight proteins such as α_1 -microglobulin, retinol-binding protein, or β_2 -microglobulin), or both. Regardless of the cause of proteinuria, blockers of the renin-angiotensin system (RAS), such as angiotensin receptor blockers or angiotensin-converting enzyme (ACE) inhibitors, are usually prescribed to decrease proteinuria and therefore slow down kidney damage. Indeed, proteinuria is a well-established risk factor for progressive kidney disease^[1,2]. Increased glomerular capillary pressure may induce excessive filtration of plasma proteins and podocyte dysfunction. The increased reabsorption of plasma proteins by proximal tubular cells may be toxic and lead to their apoptosis and interstitial fibrosis^[1,3]. This paradigm recently changed with the discovery of pathogenic variants in the cubilin (*CUBN*) gene^[4] that may cause nondetrimental proteinuria. We report the case of two siblings with such variants and discuss their clinical management.

CLINICAL CASE

An 8-year-old girl of Turkish origin with no relevant medical history presented to the Pediatric Nephrology clinic for nocturnal enuresis. An initial check-up revealed isolated mild proteinuria (protein/creatinine ratio 1.2 g/g), consisting predominantly of albuminuria. The estimated glomerular filtration rate (eGFR) was normal, as was the ultrasound of the kidneys. A kidney biopsy was performed but it only contained a single glomerulus with a normal appearance by light microscopy. Immunofluorescence was negative. Enalapril was started at 2.5 mg/day. She remained on this medication for 15 years, and proteinuria remained stable at 0.7 g/g to 1.2 g/g despite an increase in enalapril dosage up to 15 mg/day. Enalapril was poorly tolerated, with frequent episodes of orthostatic hypotension. eGFR remained completely normal.

Her younger brother was also found to have moderate isolated proteinuria (0.9 g/g) during a check-up for a hyperactive bladder. His kidney biopsy showed eight normal glomeruli by light microscopy. Immunofluorescence was negative. Enalapril was started, and proteinuria remained stable at 0.6–0.9 g/g over the course of eight years, with preserved eGFR. Both parents have normal urinalysis without proteinuria. The first genetic testing was performed in 2018 in both siblings with a panel including 20 genes related to proteinuria. Results were not contributive, as a single variant of uncertain significance (VUS) of the *ACTN4* (actinin alpha 4) gene was found in the sister but not in her brother. Updated genetic testing performed in 2022 [next generation sequencing (NGS) panel enriched for 40 genes important for proteinuric renal diseases]^[5] revealed in both siblings the presence of a pathogenic nonsense variant [American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) class 5] together with a potential splice-disrupting variant (ACMG/AMP class 3) in the *CUBN* (NM_001081.4):c.703 C > T (p.Arg235ter) and c.10363-3A > G (p.?). *CUBN* is dominated by 27 contiguous CUB domains, and variants occurring within the C-terminal (after the CUB8 domain) are usually associated with isolated proteinuria. Here, p.R235* led to truncation before CUB8, but none of the patients presented with low levels of vitamin B12 or megaloblastic anemia. Enalapril was therefore discontinued in both patients.

DISCUSSION

The proximal tubule reabsorbs large amounts of low-molecular-weight proteins but also albumin and electrolytes from the glomerular filtrate. Megalin (LRP2), *CUBN*, and amnionless (AMN) protein are located in the apical part of proximal tubular cells and are responsible for receptor-mediated endocytosis of proteins filtered through the glomerular barrier^[3]. Cubilin has been shown to have an essential role in albumin reabsorption and is encoded by the *CUBN* gene [Figure 1]^[6]. Biallelic pathogenic variants in the *CUBN* gene cause Imerslund-Gräsbeck syndrome (OMIM 261100), also called selective vitamin B12 (cobalamin) malabsorption with proteinuria^[6]. In this syndrome, which results in megaloblastic anemia responsive to parenteral vitamin B12 therapy, half of the patients present with mild proteinuria and normal




Figure 1. Albumin reabsorption in proximal tubular cells. Cubilin is located in the apical part of proximal tubular cells and is responsible for receptor-mediated endocytosis of albumin filtered through the glomerular barrier. After the decoupling of cubilin-albumin ligation, albumin is released from the basolateral cell surface into the circulation.

eGFR. The megaloblastic anemia arises from a defect in the receptor for the vitamin B12-intrinsic factor complex in ileal enterocytes. CUBN and AMN proteins represent the two subunits of this receptor. In patients with Imerslund-Gräsbeck syndrome, proteinuria can persist for decades^[7,8]. Most pathogenic variants in *CUBN* are located in the N-terminal half of the gene [Figure 2].

Recently, biallelic pathogenic variants in the C-terminal domain of *CUBN* were described as leading to isolated chronic proteinuria^[4]. Indeed, Bedin *et al.*^[4] identified 39 patients with biallelic *CUBN* variants among 2,216 individuals with suspected genetic kidney disease, including proteinuric patients. Proteinuria ranged from 0.5-3 g/day with an average age at discovery of 10.9 years. When measured, albuminuria represented more than half of proteinuria, and β 2-microglobulin urine levels were low or absent. Kidney biopsies were available in 19 patients and did not show any specific lesion in 11 patients. Four kidney biopsies underwent electron microscopy (EM) evaluation; two were normal and two revealed glomerular synechiae. The use of ACE inhibitors did not lower proteinuria, which remained stable over the years. eGFR was normal in all patients, even those older than 50 years. Bedin *et al.*^[4] also identified a phenotype-genotype correlation. Indeed, variants located after the CUB8 domain (included in the vitamin B12/intrinsic factor binding region) lead to isolated proteinuria, whereas variants located before the CUB8 domain result in Imerslund-Gräsbeck syndrome, a finding suggesting that there are separate binding sites in cubilin for




Figure 2. Cubilin protein structure. Cubilin (CUBN) is a 460 kDa glycoprotein with no transmembrane domain. It acts as a receptor for intrinsic factor-vitamin B12 complexes. There are 27 CUB domains. The intrinsic factor and the vitamin B12 binding region are located in domains 5 to 8. The precise location of the binding sites for albumin remains unclear, but it is supposed to be in the CUB domains near the C-terminal area. IGS: Imlerslund-Grasbäck syndrome; IF: intrinsic factor.

vitamin B12-intrinsic factor (VitB12-IF) and albumin; however, the precise location of the binding sites for albumin remains unclear [Figure 2]. The latter should thus bind to more carboxy-terminal CUB domains. However, the isolated proteinuria caused by the p.R235* variant located before CUB8 and leading to premature truncation of cubilin illustrates how it remains complex to determine with certainty the resulting phenotype. In addition, four specific C-terminal variants have previously shown strong associations with albuminuria in genome wide association (GWAS)^[9-13]. These *CUBN* variants were associated with higher eGFR in the study by Bedin *et al.*^[4].

In another recent cohort, Domingo-Gallego *et al.*^[14] identified 15 patients with mild proteinuria (0.5-1.8 g/day) having homozygous or compound heterozygous pathogenic variants in the C-terminal region of the *CUBN* protein. In most cases, proteinuria was detected incidentally, as in our patients. They confirmed the glomerular nature of proteinuria, normal kidney histology, lack of response to RAS blockade, and preserved eGFR in adulthood. Six children from Turkey were also identified with biallelic *CUBN* pathogenic variants located in the C-terminal domain of the protein^[15]. One child had a second kidney biopsy three years after the first normal kidney biopsy. This second biopsy revealed one area of periglomerular fibrosis among 27 glomeruli. Yang *et al.*^[16] also reported glomerulosclerosis and effacement of foot processes in podocytes on EM in three children with *CUBN* pathogenic variants. The authors suggested a role for podocyte dysfunction together with a defect in the reuptake of albumin in the proximal tubule of patients with *CUBN* mutations. These data need to be confirmed. Indeed, these structural changes in podocytes were absent in two children on EM^[17]. These authors showed that *CUBN* variants induce changes in the scaffolding capabilities of cubilin protein *in vitro*. These changes reduce the interactions between CUB and AMN, leading to an aberrant localization of AMN in the cytoplasm of proximal tubular cells instead of the cell membrane. This may interrupt the receptor-mediated endocytosis that re-uptakes filtered albumin.

In conclusion, in the absence of functional cubilin in proximal tubular cells, albumin reabsorption is incomplete, and this leads to mild albuminuria. This mechanism acts downstream of the glomerular barrier, and does not affect the intraglomerular pressure, and is thus not expected to damage podocytes. This explains why anti-proteinuric agents such as ACE inhibitors do not succeed in lowering this particular

proteinuria. Detection of *CUBN* pathogenic variants is crucial in clinical nephrology because it prevents unnecessary kidney biopsies as well as the use of RAS blockers and their potential side effects, such as symptomatic hypotension or, rarely, angioneurotic edema. The benign course of this disease needs to be confirmed by longer-term follow-up.

DECLARATIONS

Authors' contributions

Contributed to the concept, design, draft, and revision of this manuscript: Gillion V, Dahan K, Godefroid N

Availability of data and materials

Not applicable.

Financial support and sponsorship

None.

Conflicts of interest

All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate

Ethics approval was deemed unnecessary according to national regulations (i.e., the Belgian law of 7/5/2004 concerning experiments on human subjects). All participants provided written consent to participate in this study.

Consent for publication

Not applicable.

Copyright

© The Author(s) 2023.

REFERENCES

1. Roscioni SS, Lambers Heerspink HJ, de Zeeuw D. Microalbuminuria: target for renoprotective therapy PRO. *Kidney Int.* 2014;86:40-9. [PubMed](#)
2. Hemmelgarn BR, Manns BJ, Lloyd A, et al.; Alberta Kidney Disease Network. Relation between kidney function, proteinuria, and adverse outcomes. *JAMA.* 2010;303:423-9. [DOI](#)
3. Quinlan C. *CUBN* variants uncouple proteinuria from kidney function. *Nat Rev Nephrol.* 2020;16:135-6. [DOI](#) [PubMed](#)
4. Bedin M, Boyer O, Servais A, et al. Human C-terminal *CUBN* variants associate with chronic proteinuria and normal renal function. *J Clin Invest.* 2020;130:335-44. [DOI](#) [PubMed](#) [PMC](#)
5. Knoers N, Antignac C, Bergmann C, et al. Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice. *Nephrol Dial Transplant.* 2022;37:239-54. [DOI](#) [PubMed](#) [PMC](#)
6. Amsellem S, Gburek J, Hamard G, et al. Cubilin is essential for albumin reabsorption in the renal proximal tubule. *J Am Soc Nephrol.* 2010. 1859-67 [DOI](#) [PubMed](#) [PMC](#)
7. Gräsbeck R. Imerslund-Gräsbeck syndrome (selective vitamin B₁₂ malabsorption with proteinuria). *Orphanet J Rare Dis.* 2006;1:17. [DOI](#)
8. Aminoff M, Carter JE, Chadwick RB, et al. Mutations in *CUBN*, encoding the intrinsic factor-vitamin B12 receptor, cubilin, cause hereditary megaloblastic anaemia 1. *Nat Genet.* 1999;21:309-13. [DOI](#)
9. Ahluwalia TS, Schulz CA, Waage J, et al. A novel rare *CUBN* variant and three additional genes identified in Europeans with and without diabetes: results from an exome-wide association study of albuminuria. *Diabetologia.* 2019;62:292-305. [DOI](#) [PubMed](#) [PMC](#)
10. Böger CA, Chen MH, Tin A, et al.; CKDGen Consortium. *CUBN* is a gene locus for albuminuria. *J Am Soc Nephrol.* 2011;22:555-70. [DOI](#)
11. Haas ME, Aragam KG, Emdin CA, et al.; International Consortium for Blood Pressure. Genetic association of albuminuria with cardiometabolic disease and blood pressure. *Am J Hum Genet.* 2018;103:461-73. [DOI](#) [PubMed](#) [PMC](#)
12. Zanetti D, Rao A, Gustafsson S, Assimes TL, Montgomery SB, Ingelsson E. Identification of 22 novel loci associated with urinary

- biomarkers of albumin, sodium, and potassium excretion. *Kidney Int.* 2019;95:1197-208. [PubMed](#) [PMC](#)
13. Teumer A, Tin A, Sorice R, et al.; DCCT/EDIC. Genome-wide association studies identify genetic loci associated with albuminuria in diabetes. *Diabetes.* 2016;65:803-17. [DOI](#)
 14. Domingo-Gallego A, Pybus M, Madariaga L, et al. Clinical and genetic characterization of a cohort of proteinuric patients with biallelic CUBN variants. *Nephrol Dial Transplant.* 2022;37:1906-15. [DOI](#)
 15. Cicek N, Alpay H, Guven S, et al. Clinical and genetic characterization of children with cubilin variants. *Pediatr Nephrol.* 2023;38:1381-5. [DOI](#)
 16. Yang J, Xu Y, Deng L, et al. CUBN gene mutations may cause focal segmental glomerulosclerosis (FSGS) in children. *BMC Nephrol.* 2022;23:15. [DOI](#) [PubMed](#) [PMC](#)
 17. Gan C, Zhou X, Chen D, et al. Novel pathogenic variants in CUBN uncouple proteinuria from renal function. *J Transl Med.* 2022;20:480. [DOI](#) [PubMed](#) [PMC](#)